Opinion on Diabetic Complications

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Lucentis shows potential in diabetic macular edema

A US National Eye Institute Phase III clinical trial of Lucentis in diabetic macular edema has demonstrated a beneficial effect in combination with laser therapy. While Lucentis already dominates the macular degeneration market with a 95% global market share in 2009, Datamonitor sees potential for the drug to gain approval in the untapped diabetic macular edema market.

Published By Datamonitor
29 Apr 2010
CommentWire
CommentWire

Roche: Phase III results raise hopes for additional ophthalmic indication for Lucentis

Encouraging trial data presented at this year's American Diabetes Association meeting reveal that Roche's Lucentis significantly improves visual acuity among patients with diabetic macular edema. If approved by the FDA, this would give Lucentis a third indication within the US ophthalmic market. Nevertheless, off-label use of Avastin may temper sales.

Published By Datamonitor
01 Jul 2011

« | 1 | » »|

No help is available.